{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T14:54:58Z","timestamp":1773500098642,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T00:00:00Z","timestamp":1559865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004316","name":"International Business Machines Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.ahj.2019.06.005","type":"journal-article","created":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T23:56:10Z","timestamp":1560297370000},"page":"30-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease"],"prefix":"10.1016","volume":"216","author":[{"given":"Christopher P.","family":"Cannon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irfan","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa C.","family":"Klimchak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Sasiela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph M.","family":"Massaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph B.","family":"D'Agostino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2019.06.005_bb0005","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2019.06.005_bb0010","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ahj.2019.06.005_bb0015","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ahj.2019.06.005_bb0020","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ahj.2019.06.005_bb0025","series-title":"2018;pii: S0735\u20131097(18)39034-X","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol","author":"Grundy","year":"2018"},{"key":"10.1016\/j.ahj.2019.06.005_bb0030","first-page":"1785","article-title":"2017 Focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk","volume":"70","author":"Lloyd-Jones","year":"2017","journal-title":"a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.06.005_bb0035","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2019.06.005_bb0040","first-page":"2245","article-title":"European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk","volume":"38","author":"Landmesser","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2019.06.005_bb0045","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jamacardio.2017.2289","article-title":"Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease","volume":"2","author":"Cannon","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2019.06.005_bb0050","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1046\/j.1525-1497.1999.10198.x","article-title":"Positive predictive value of the diagnosis of acute myocardial infarction in an administrative database","volume":"14","author":"Petersen","year":"1999","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.ahj.2019.06.005_bb0055","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCOUTCOMES.113.000743","article-title":"Validity of claims-based stroke algorithms in contemporary Medicare data: reasons for geographic and racial differences in stroke (REGARDS) study linked with Medicare claims","volume":"7","author":"Kumamaru","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ahj.2019.06.005_bb0060","unstructured":"National Technical Information Service. Department of Commerce. Limited access death master file Available at: https:\/\/classic.ntis.gov\/products\/ssa-dmf\/#."},{"key":"10.1016\/j.ahj.2019.06.005_bb0065","unstructured":"National Center for Health Statistics. Centers for Disease Control and Prevention Available at: https:\/\/www.cdc.gov\/nchs\/products\/life_tables.htm."},{"key":"10.1016\/j.ahj.2019.06.005_bb0075","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.amjcard.2019.01.028","article-title":"Simulation of the impact of statin intolerance on the need for ezetimibe and\/or proprotein convertase subtilisin\/kexin type 9 inhibitor for meeting lowdensity lipoprotein cholesterol goals in a population with atherosclerotic cardiovascular disease","volume":"123","author":"Cannon","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2019.06.005_bb0080","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1161\/CIRCULATIONAHA.117.028430","article-title":"Proprotein convertase subtilisin\/kexin type 9 inhibitor therapy: Payer approvals and rejections, and patient characteristics for successful prescribing","volume":"136","author":"Hess","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2019.06.005_bb0085","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jacc.2015.10.077","article-title":"Reduction in total cardiovascular events with ezetimibe\/simvastatin post-acute coronary syndrome: the IMPROVE-IT Trial","volume":"67","author":"Murphy","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.06.005_bb0090","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jacc.2018.10.039","article-title":"Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial","volume":"73","author":"Szarek","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.06.005_bb0095","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1136\/bmj.320.7247.1446","article-title":"Thresholds for taking antihypertensive drugs in different professional and lay groups: questionnaire survey","volume":"320","author":"Steel","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2019.06.005_bb0100","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jamacardio.2017.2293","article-title":"Low-density lipoprotein cholesterol treatment in the proprotein convertase subtilisin\/kexin type 9 inhibitor era: getting back on target","volume":"2","author":"Sabatine","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2019.06.005_bb0105","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jacl.2016.06.011","article-title":"Prevalence of the American College of Cardiology\/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012","volume":"10","author":"Wong","year":"2016","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.ahj.2019.06.005_bb0110","first-page":"2183","article-title":"Implications of the 2013 ACC\/AHA cholesterol guidelines for adults in contemporary cardiovascular practice","volume":"64","author":"Maddox","year":"2014","journal-title":"insights from the NCDR PINNACLE registry. J Am Coll Cardiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319301504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319301504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:56:50Z","timestamp":1762077410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870319301504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":21,"alternative-id":["S0002870319301504"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2019.06.005","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2019.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}